OPKO Health/$OPK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About OPKO Health
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Ticker
$OPK
Sector
Primary listing
Employees
2,997
Headquarters
Website
OPKO Health Metrics
BasicAdvanced
$1.1B
-
-$0.26
1.19
-
Price and volume
Market cap
$1.1B
Beta
1.19
52-week high
$2.04
52-week low
$1.11
Average daily volume
2.2M
Financial strength
Current ratio
3.408
Quick ratio
2.205
Long term debt to equity
28.547
Total debt to equity
30.514
Interest coverage (TTM)
-2.28%
Profitability
EBITDA (TTM)
-172.847
Gross margin (TTM)
14.52%
Net profit margin (TTM)
-26.68%
Operating margin (TTM)
-40.29%
Effective tax rate (TTM)
-16.15%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-8.46%
Return on equity (TTM)
-13.16%
Valuation
Price to revenue (TTM)
1.441
Price to book
0.83
Price to tangible book (TTM)
17.43
Price to free cash flow (TTM)
-3.69
Free cash flow yield (TTM)
-27.10%
Free cash flow per share (TTM)
-0.374
Growth
Revenue change (TTM)
-7.31%
Earnings per share change (TTM)
-23.60%
3-year revenue growth (CAGR)
-22.50%
10-year revenue growth (CAGR)
18.88%
3-year earnings per share growth (CAGR)
-5.42%
10-year earnings per share growth (CAGR)
-8.04%
What the Analysts think about OPKO Health
Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Bulls say / Bears say
OPKO’s Phase 3 Japan trial for once-weekly somatrogon met both primary and secondary endpoints with efficacy and safety comparable to daily Genotropin, de-risking its growth hormone deficiency program (Reuters)
OPKO and Entera Bio have launched a collaboration to develop a once-daily oral GLP-1 obesity pill targeting a market projected to reach $150 billion by 2030, diversifying OPKO’s pipeline into high-growth metabolic therapies (Reuters)
The Entera partnership extends beyond obesity into metabolic and fibrotic disorders, broadening OPKO’s clinical scope into areas with unmet medical need and potential for premium pricing (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
OPKO Health Financial Performance
Revenues and expenses
OPKO Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for OPKO Health stock?
OPKO Health (OPK) has a market cap of $1.1B as of September 16, 2025.
What is the P/E ratio for OPKO Health stock?
The price to earnings (P/E) ratio for OPKO Health (OPK) stock is 0 as of September 16, 2025.
Does OPKO Health stock pay dividends?
No, OPKO Health (OPK) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next OPKO Health dividend payment date?
OPKO Health (OPK) stock does not pay dividends to its shareholders.
What is the beta indicator for OPKO Health?
OPKO Health (OPK) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.